House Resolution 8015 is a ceremonial resolution that recognizes June 10, 2026, as “FSGS Awareness Day” in Florida. The resolution focuses on focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease that causes scarring in the kidneys and can progress to kidney failure, dialysis, or transplant. It includes findings about the prevalence of chronic kidney disease in Florida, the severity and recurrence risk of FSGS, and the importance of raising awareness for patients and families affected by the disease.
The resolution also highlights the role of public awareness and fundraising efforts, specifically referencing the Tampa Pig Jig as an example of community support for FSGS research. Its stated purpose is to encourage better diagnosis, support for patients, and future treatment development. Because it is a resolution rather than a regulatory bill, it does not create new legal requirements or alter substantive state law; instead, it formally designates a commemorative day in Florida.
Impact
H8015 has no direct regulatory or fiscal impact on Florida statutes or agencies. It does not amend the Florida Statutes, create a program, appropriate funds, or impose duties on any person or government entity. Its legal effect is limited to a legislative recognition of June 10, 2026, as FSGS Awareness Day, serving primarily as a public awareness and commemorative measure for a rare kidney disease and the patients, families, and advocacy groups affected by it.
Sentiment
The overall sentiment around the resolution appears strongly supportive and noncontroversial. The bill’s language is sympathetic and advocacy-oriented, emphasizing the seriousness of FSGS, the burden of kidney disease in Florida, and the value of awareness, research, and patient support. No committee transcripts or recorded votes were provided, and there is no indication of opposition or debate in the available materials.
Contention
No notable points of contention are evident in the available record. The resolution is framed as a recognition measure and does not appear to raise policy disputes, budget concerns, or regulatory objections. Any discussion implied by the text centers on public health awareness, rare disease advocacy, and support for research and treatment access rather than disagreement over legislative authority or implementation.